Clinical Trial Search

Primary: The Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) From Baseline at Week 12. — 18; 132 Participants — p=<0.001

Primary: Change in Appetite as Measured by ESAS — -0.83; -1.19 units on a scale

Primary: Change From Parent Study Baseline in Mean Pain 0-10 Numerical Rating Scale (NRS) Score During the Last 4 Weeks of Open-label Treatment — -2.07 units on a scale

Primary: Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period — 125 Participants

Primary: Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1) — -0.025; 0.062; 0.099 L — p=<0.0001

Primary: Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1) — 0.034; 0.072 L

Primary: The Incidence of Adverse Events as a Measure of Subject Safety — 37; 4 participants

Primary: Progression-Free Survival (PFS) Determined by an Independent Review Facility — 18.5; 12.4 Months — p=<0.0001

Primary: Response to Treatment Defined as Patients Who Decrease Their Detrusor Leak Point Pressure (LPP) to <40 cm H2O Based Upon Two Evaluations on the Same Day. — 35.3; 45.7…

Primary: Beck Depression Inventory-II — 16.1; 14.8 units on a scale

Primary: Time to Progression — 15; 9.6 months

Primary: Responder Rate at Month 6 in the Per Protocol Population Using the Subjective Well-being Under Neuroleptics Scale, Short Version (SWN-K) Total Score — 136; 158…

Primary: Change From Baseline in Single-Hand Nail Psoriasis Severity Index (NAPSI)and in the Modified Target NAPSI for the Single Most Severely Affected Nail of Each Hand at Week…

Primary: Change From Baseline in the Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) 18-Item Total…

Primary: Seizure Frequency